Adenoviral gene therapy for pancreatic cancer: where do we stand?
Koert F D Kuhlmann1, Dirk J Gouma, John G Wesseling
1Department of Surgery, AMC Liver Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. k.f.kuhlmann@amc.uva.nl
Background:
The prognosis of patients with pancreatic cancer is poor. This is mainly caused by the late diagnosis, the aggressive biology and the lack of effective treatment modalities. Adenoviral gene therapy has the potential to selectively treat both primary tumor and (micro)metastatic tissue.
Methods:
This review provides an overview of what has been achieved so far in the field of adenoviral gene therapy for pancreatic cancer.
Results:
Transductional targeting allows decreased toxicity due to vector dissemination to non-target cells and permits delivery with a lower viral dose. It can evade or diminish the immune response, which remains a major problem. Transcriptional targeting evolves quickly but essential drawbacks such as the lack of an efficient animal model delay clinical application. Few clinical trials utilizing adenoviruses have been performed in patients with pancreatic cancer today. Worldwide, only seven phase III trials are being performed investigating adenoviral vectors in cancer patients.
Conclusion:
A clear therapeutic effect of adenoviral gene therapy in pancreatic cancer has not yet been achieved, because the step from bench to bedside has encountered drawbacks. Combinations of the different targeting strategies and techniques to evade the immune system harbor the future for adenoviral gene therapy in patients with pancreatic cancer.
Insights
Adenoviral gene therapy shows promise for pancreatic cancer, but challenges like immune response and animal models hinder clinical use. Future strategies involve combining targeting methods and immune evasion techniques.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Pancreatic cancer has a poor prognosis due to late diagnosis and limited treatment options.
- Adenoviral gene therapy offers potential for targeted treatment of primary and metastatic pancreatic tumors.
Purpose of the Study:
- To review the current achievements in adenoviral gene therapy for pancreatic cancer.
Main Methods:
- Review of existing literature on adenoviral gene therapy strategies.
- Analysis of transductional and transcriptional targeting methods.
- Evaluation of clinical trial data and challenges.
Main Results:
- Transductional targeting reduces toxicity and immune response.
- Transcriptional targeting shows promise but is limited by a lack of effective animal models.
- Clinical application is hindered by challenges in vector dissemination and immune evasion.
Conclusions:
- Adenoviral gene therapy has not yet achieved significant therapeutic effects in pancreatic cancer.
- Combining targeting strategies and immune evasion techniques is crucial for future success.
More Related Videos
Related Concept Videos
00:59Gene Therapy
00:59Gene Therapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers